BetterLife Pharma TD-0148A Phase I

BetterLife is focused on developing second-generation psychedelic compounds and novel neuropharmacological drugs; addressing unmet needs within the mental health, wellness and anti-ageing industries.

TD-0148A is a non-hallucinogenic second-generation Lysergic Acid Diethylamide (“LSD”) derivative molecule that mimics the projected therapeutic potential of LSD in the treatment of disorders such as depression, PTSD, and migraines.

Compound LSD
Country United States of America
Visit trial
Status Planned
Results Published
Start date 01 January 2023
End date 01 July 2023
Chance of happening 60%
Phase Phase I
Design Open
Type Interventional
Generation Second
Participants 10
Sex All
Therapy No

Trial Details



NCT Number

Sponsors & Collaborators

BetterLife Pharma
BetterLife Pharma is a life sciences company that aims to develop 'second generation' psychedelics that provide the therapeutic benefits without the trip.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.